Pfizer receives conditional marketing authorization for Bosulif

Pfizer has announced its Bosulif medication has been granted conditional marketing authorisation in the European Union.

The pharmaceutical company confirmed the drug will provide a new treatment option for patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia.

According to the company, Busolif is set to be provided to individuals who have previously been administered more tyrosine kinase inhibitors and for whom imatinib, nilotinib and dasatinib are not considered appropriate options.

Conditional marketing authorisations in the European Union are granted to medicinal products with a positive benefit assessment that address unmet medical needs and would provide a significant public health benefit.

Carlo Gambacorti-Passerini, professor of Internal Medicine at the University of Milano Bicocca in Italy, said: "Based on my experience with Bosulif, I believe this once-daily treatment, with its distinct safety profile, offers an important new alternative."

He also noted it is important patients living with leukemia are provided with more treatment options due to their varying medical needs.